An artificial intelligence model for embryo selection in preimplantation DNA methylation screening in assisted reproductive technology

• Published in: Biophysics reports Vol. 9; no. 6; pp. 352 - 361
• Main Authors: Zhan, Jianhong, Chen, Chuangqi, Zhang, Na, Zhong, Shuhuai, Wang, Jiaming, Hu, Jinzhou, Liu, Jiang
• Format: Journal Article
• Language: English
• Published: China Institute of Biophysics 31.12.2023; Biophysics Reports Editorial Office
• Subjects: Aneuploidy; Artificial intelligence; Biomarkers; Deoxyribonucleic acid; DNA; DNA methylation; Embryos; Genetic screening; Genetic testing; Reproductive technologies; DNA methylation; Assisted reproductive technology; Artificial intelligence; Embryo selection
• ISSN: 2364-3420; 2364-3439; 2364-3420
• DOI: 10.52601/bpr.2023.230035

Embryo quality is a critical determinant of clinical outcomes in assisted reproductive technology (ART). A recent clinical trial investigating preimplantation DNA methylation screening (PIMS) revealed that whole genome DNA methylation level is a novel biomarker for assessing ART embryo quality. Here, we reinforced and estimated the clinical efficacy of PIMS. We introduce PIMS-AI, an innovative artificial intelligence (AI) based model, to predict the probability of an embryo producing live birth and subsequently assist ART embryo selection. Our model demonstrated robust performance, achieving an area under the curve (AUC) of 0.90 in cross-validation and 0.80 in independent testing. In simulated embryo selection, PIMS-AI attained an accuracy of 81% in identifying viable embryos for patients. Notably, PIMS-AI offers significant advantages over conventional preimplantation genetic testing for aneuploidy (PGT-A), including enhanced embryo discriminability and the potential to benefit a broader patient population. In conclusion, our approach holds substantial promise for clinical application and has the potential to significantly improve the ART success rate.